Avalyn Pharma Inc. reported financial results for the quarter ended June 30, 2026, reporting a net loss of $28.9 million compared to $20.2 million in the prior year period. Research and development expenses increased to $24.7 million from $17.9 million, while general and administrative expenses rose to $6.6 million from $3.9 million. The company ended the quarter with $413.5 million in cash, cash equivalents, and marketable securities, projecting a cash runway into 2029. Clinically, Avalyn completed enrollment of its global Phase 2b MIST trial for AP01 with 398 patients, with topline data expected in the second half of 2027. The company operates as a clinical-stage biopharmaceutical firm developing inhaled therapies for rare respiratory diseases.

On June 29, 2026, Avalyn Pharma Inc. entered into a First Amendment to its Sublease Agreement with CRISPR Therapeutics, Inc. The amendment expands the company's leased premises in Boston, Massachusetts from approximately 8,774 to 13,708 rentable square feet. This expansion increases the company's future minimum lease payments by approximately $924,000 over the remaining lease term. Avalyn Pharma Inc. is a pharmaceutical company.

Avalyn Pharma Inc. announced on June 17, 2026, that it has completed target enrollment for its Phase 2b MIST trial of AP01 (inhaled pirfenidone) for patients with progressive pulmonary fibrosis. Avalyn Pharma Inc. is a pharmaceutical company focused on developing therapeutic solutions for pulmonary diseases.